Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens

INTRODUCTION: Based on the variable benefit of taxanes in the adjuvant setting of early breast cancer in certain tumor phenotypes, especially in human epidermal growth factor receptor (HER)2-positive and triple-negative disease, and with the observation of a lesser benefit in luminal A, this researc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kader, Yasser Abdel, El-Nahas, Tamer, Sakr, Amr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745289/
https://www.ncbi.nlm.nih.gov/pubmed/23966793
http://dx.doi.org/10.2147/OTT.S48397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745289/
https://www.ncbi.nlm.nih.gov/pubmed/23966793
http://dx.doi.org/10.2147/OTT.S48397

Ejemplares similares